Hippocalcin‐like 1 suppresses hepatocellular carcinoma progression by promoting p21Waf/Cip1 stabilization by activating the ERK1/2‐MAPK pathway

Yonglong Zhang, Yanfeng Liu, Jinlin Duan, Haibo Yan, Jun Zhang, Huilu Zhang, Qi Fan, Feifei Luo, Guoquan Yan, Ke Qiao, Jie Liu – 13 December 2015 – Hepatocellular carcinoma (HCC) is the third leading cause of cancer‐related death. However, the underlying mechanism during hepatocarcinogenesis remains unclarified. Stable isotope labeling by amino acids in cell culture (SILAC) is a powerful quantitative strategy for proteome‐wide discovery of novel biomarkers in cancers. Hippocalcin‐like 1 (HPCAL1) is a calcium sensor protein.

Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study

Marta Cavallin, Salvatore Piano, Antonietta Romano, Silvano Fasolato, Anna Chiara Frigo, Gianpiero Benetti, Elisabetta Gola, Filippo Morando, Marialuisa Stanco, Silvia Rosi, Antonietta Sticca, Umberto Cillo, Paolo Angeli – 13 December 2015 – In patients with cirrhosis and hepatorenal syndrome (HRS), terlipressin has been used either as continuous intravenous infusion or as intravenous boluses. To date, these two approaches have never been compared.

MEP1A contributes to tumor progression and predicts poor clinical outcome in human hepatocellular carcinoma

Han‐Yue OuYang, Jing Xu, Jun Luo, Ru‐Hai Zou, Keng Chen, Yong Le, Yong‐Fa Zhang, Wei Wei, Rong‐Ping Guo, Ming Shi – 13 December 2015 – Although many staging classifications have been proposed for hepatocellular carcinoma (HCC), determining a patient's prognosis in clinical practice is a challenge due to the molecular diversity of HCC. We investigated the relationship between MEP1A, a candidate oncogene, and clinical outcomes of HCC patients; furthermore, we explored the role of MEP1A in HCC.

Identification of p38 MAPK and JNK as new targets for correction of Wilson disease‐causing ATP7B mutants

Giancarlo Chesi, Ramanath N. Hegde, Simona Iacobacci, Mafalda Concilli, Seetharaman Parashuraman, Beatrice Paola Festa, Elena V. Polishchuk, Giuseppe Di Tullio, Annamaria Carissimo, Sandro Montefusco, Diana Canetti, Maria Monti, Angela Amoresano, Piero Pucci, Bart van de Sluis, Svetlana Lutsenko, Alberto Luini, Roman S. Polishchuk – 13 December 2015 – Wilson disease (WD) is an autosomal recessive disorder that is caused by the toxic accumulation of copper (Cu) in the liver.

Identification of p38 MAPK and JNK as new targets for correction of Wilson disease‐causing ATP7B mutants

Giancarlo Chesi, Ramanath N. Hegde, Simona Iacobacci, Mafalda Concilli, Seetharaman Parashuraman, Beatrice Paola Festa, Elena V. Polishchuk, Giuseppe Di Tullio, Annamaria Carissimo, Sandro Montefusco, Diana Canetti, Maria Monti, Angela Amoresano, Piero Pucci, Bart van de Sluis, Svetlana Lutsenko, Alberto Luini, Roman S. Polishchuk – 13 December 2015 – Wilson disease (WD) is an autosomal recessive disorder that is caused by the toxic accumulation of copper (Cu) in the liver.

Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study

Marta Cavallin, Salvatore Piano, Antonietta Romano, Silvano Fasolato, Anna Chiara Frigo, Gianpiero Benetti, Elisabetta Gola, Filippo Morando, Marialuisa Stanco, Silvia Rosi, Antonietta Sticca, Umberto Cillo, Paolo Angeli – 13 December 2015 – In patients with cirrhosis and hepatorenal syndrome (HRS), terlipressin has been used either as continuous intravenous infusion or as intravenous boluses. To date, these two approaches have never been compared.

Subscribe to